…s two-fold higher in patients diagnosed with IM during adolescence (ages 11-19 years) compared to those with an IM diagnosis in early childhood (hazard ratio 2.46) or adulthood (HR 2.06). Anti-CD20 therapy effective after natalizumab Two studies have examined the safety and efficacy of ofatumumab in patients discontinuing natalizumab. An Italian real-world study followed 38 patients who had switched from natalizumab to ofatumumab for >3 months (Ca…

…ion for people with MS (Odogwu et al. ECTRIMS 2024;P538). An analysis of the MS Register in the U.K. (N=12,293) found that disability scores were only slightly higher in current smokers compared to ex-smokers who now vape. Disability scores were lowest in non-smokers and ex-smokers who did not vape. Friday Edition Thursday Edition…

…olimod tapering to reduce rebound Artificial intelligence applied to an MS database MS-STAT2 trial of simvastatin in SPMS Phase III trials (GEMINI I/II, HERCULES) of tolebrutinib in RMS and SPMS Question 5: About which oral disease-modifying therapy would you like more information? (pick 2) Cladribine Dimethyl fumarate Fingolimod Ozanimod Ponesimod Siponimod Teriflunomide Question 6: About which monoclonal antibody disease-modifying therapy would…